Full Press Release Details
SOUTH SAN FRANCISCO, Calif., June 01, 2018 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX) a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody™ therapeutic technology platform, today announced that it will host a conference call and live webcast on Monday, June 4th at 5:00 p.m. CT/ 6:00 p.m. ET to discuss presentations of preliminary clinical results from PROCLAIM-072, an ongoing Phase 1/2 trial evaluating CX-072, a Probody therapeutic targeting PD-L1, at the 2018 Annual Meeting of the American Society of Clinical Oncology (ASCO). Conference call and webcast details are as follows:
Monday, June 4, 2018
5:00 p.m. Central Time/ 6:00 p.m. Eastern Time
Audio Conference Call:
U.S. Toll Free Dial-in Number: (877) 809-6037
International Dial-in Number: (615) 247-0221
Conference ID: 4294667
Access the Events and Presentations Section of CytomX’s Investor Relations section at http://ir.cytomx.com/events-and-presentations
Access the website 15 minutes prior to the start of the call to download and install any necessary audio software with slides
A replay of the webcast will be archived and available on CytomX’s website for three months following the event.
About CytomX Therapeutics
VP, Investor Relations and Corporate Communications